Rapsgatan 7E
Uppsala
Sweden
46 1 87 80 88 00
https://www.orexo.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 116
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Nikolaj Sorensen | President & CEO | 5.78M | N/A | 1972 |
Mr. Fredrik Jarrsten | Executive VP & CFO | N/A | N/A | 1967 |
Ms. Cecilia Coupland | Senior VP & Head of Operations | N/A | N/A | 1976 |
Lena Wange | Investor Relations & Communications Director | N/A | N/A | N/A |
Mr. Robert Ronn | Senior VP and Head of R&D | N/A | N/A | 1976 |
Dr. Edward Kim M.B.A., M.D. | Chief Medical Officer | N/A | N/A | N/A |
Mr. Robert A. Deluca | President of Orexo US Inc | N/A | N/A | 1961 |
Mr. Jesper Lind | Advisor | N/A | N/A | 1960 |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Orexo AB (publ)’s ISS Governance QualityScore as of March 1, 2024 is 5. The pillar scores are Audit: 8; Board: 1; Shareholder Rights: 4; Compensation: 10.